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29.6% of GPs, insoles by 8.4%, and a knee brace by 3.7%. At least one
non-pharmacological treatment was recommended by 88.1% of GPs.
Conclusions: Although most GPs in France used non-pharmacological
treatment in combination with drugs to treat patients with persistent pain
from knee osteoarthritis, the choice of non-pharmacological measures
was not always appropriate to the clinical proﬁle. Efforts are needed to
improve the use by GPs of non-pharmacological treatments in patients
with knee osteoarthritis.
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Purpose: To investigate the effectiveness of multidisciplinary outpatient
rehabilitation program (MRP), implemented 2−4 months after primary to-
tal knee arthroplasty (TKA), on functional recovery, health related quality
of life (HRQoL), and rehabilitation service utilization.
Methods: In the prospective, randomized, controlled trial a total of 88
participants were scheduled for TKA due to osteoarthritis (OA) of the
knee. Participants (n = 86) were randomized on the day of their discharge
after surgery to a control group (usual orthopedic care) or an active
group (additional 10-day MRP). Each MRP course consisted of up to 8
participants. The aim of the MRP was to improve participants’ coping with
the activities of daily living, including improvement of lower-limb strength,
increase of lower-limb joint mobility, improvement of endurance and
cardiovascular ﬁtness, and reinforcement of coping strategies. Further
objectives were motivating the participants to carry out a regular exercise
program, and weight control or weight reduction. The ﬁnal aim of the MRP
was psychosocial recreation, especially through peer support.
Assessments of both groups, performed preoperatively, and at the 2,
6, and 12-month follow-ups, included questionnaires [the Western On-
tario and McMaster Universities OA Index (WOMAC), the 15D and the
RAND 36-Item Health Survey 1.0 (RAND-36)] and physical performance
measures [15-meter (m) walk test, stair test, and isometric strength
measurement of the knee]. The use of rehabilitation services was asked
by means of a self-administered questionnaire. Response to the treatment
was analyzed at the 12 month-follow-up according to the guidelines of the
Outcome Measures in Rheumatology-Osteoarthritis Research Society
International (OMERACT-OARSI). The mixed model approach was used
to analyze repeated measurements. Pt∗g indicates time-group interaction.
Figure 1. Results of the WOMAC scores (Median and 25th-
75thpercentiles) preoperatively and at the 2, 6, and 12-month follow-ups.
Results: Self-reported disability and pain declined, objectively measured
physical performance, and HRQoL improved signiﬁcantly in both groups.
No difference was found between groups in any outcome measure during
the study period. The results of the WOMAC scores are presented in
Figure 1. In the 15D score participants in both groups reached the level
of the general public of the same age at the 12-month follow-up. The
absolute change in 3 physical domain scales of the RAND-36 (PF, BP
and RP) during the study period was 20 in both groups, indicating sig-
niﬁcant clinical improvement. Remarkable improvement, which plateaued
at 6 months, was found in the results of all physical performance tests. No
difference was found between groups in the use of additional postopera-
tive rehabilitation services (p = 0.77). According to the OMERACT-OARSI
criteria high improvement was detected in 26 (72.2%) participants of the
AG, and in 27 (69.2%) participants of the CG at the 12-month-follow-up.
Conclusions: The MRP 2−4 months after TKA did not yield faster
attainment of functional recovery than did standard orthopedic care alone.
Dramatic improvement in functional ability, pain, HRQoL, and physical
performance was gained in both groups within the ﬁrst 6 months after
surgery.
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Purpose: In the synovial ﬂuid (SF) of patients suffering from osteoarthritis
(OA) a decrease in the concentration and in the molecular weight of
hyaluronan can be observed. Therefore, treatment of OA includes intra-
articular injections of hyaluronan whereby the viscoelastic properties
of the SF are believed to be restored. During the past years it has,
however, become evident that the mechanism of action of intra-articular
injections of hyaluronan may be more than this; important interactions with
hyaluronan binding proteins and receptors may be involved. For this to
take place, the injected product needs to be recognized as hyaluronan by
the body. Current hyaluronan products for OA treatment include solutions
of puriﬁed hyaluronan as well as hyaluronan hydrogels, where the material
has been crosslinked into networks. Some of the hydrogels have been
suggested to be less biocompatible than others, which may depend on
e.g. the source and purity of the ingoing material. In addition, the chemical
structure of the crosslinked polysaccharide and thus the ability of the body
to recognise it as hyaluronan may vary substantially.
In the present study, (i) the biocompatibility of DurolaneTM in the joint
and (ii) the ability of proteins that bind hyaluronan with high speciﬁcity,
to interact with Durolane in vitro, has been investigated. Durolane is
composed of hyaluronan of bacterial origin that has been crosslinked
into a network by Q-Meds patented NASHATM manufacturing process.
The product has the appearance of a clear gel composed of small gel
particles.
Methods: Biocompatibility; Durolane was injected into the knee of anes-
thetized rabbits. This was repeated after 6 and 12 weeks (a total of three
injections). The animals were observed for adverse events, and knee joint
capsules were sectioned and studied microscopically.
Protein interactions; A complex (containing the hyaluronan binding Link
module) was puriﬁed from cartilage and labelled with Alexa-Fluor® 594
(HABCﬂ). Durolane gel particles were incubated at room temperature in
PBS containing 75mg/ml of HABCﬂ and viewed by confocal microscopy.
Probe pre-incubated with hyaluronan oligosaccharides was used as a
negative control. The degradation of Durolane by hyaluronidase was
monitored by the use of ultra ﬁltration and detection of released hyaluronic
acid (HA) oligomers using carbazole. A solution of hyaluronan of the
same concentration was degraded at the same time and by the same
conditions, as a reference.
Results: Biocompatibility studies revealed no evidence of inﬁltration of
inﬂammatory cells, necrosis, irritation or any deleterious inﬂammatory
reactions within the joint capsule and within the surrounding tissue. In the
confocal microscope, particles of Durolane appeared strongly ﬂuorescent
after incubation with HABCﬂ. The speciﬁc nature of the interaction was
conﬁrmed by the negative controls which were devoid of ﬂuorescence. In
the hyaluronidase assay, Durolane exhibited the same degradation proﬁle
as the solution of hyaluronan.
Conclusions: Durolane appears to be safe and without adverse reactions
when used for intra-articular injections. In addition, the gel could be
recognised by proteins containing the LINK module conferring normal
hyaluronan binding. Thus hyaluronan present in Durolane can interact
with hyaluronan binding proteins and is likely to confer the same signals
as endogenous hyaluronan.
